Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
None USD 0.00(0%)
Last update at 2026-11-20T21:01:38.245657Z
Market Cap
0.39M

Momentum Score

…

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana. On June 3, 2026, Inotiv, Inc. along with its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.33
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
507.36M
Revenue Per Share
14.73
Gross Profit TTM
116.41M
Debt / Equity
3.70
ROE
-74.09%
Net Debt
481.89M
ROCE
-14.55%
Diluted EPS TTM
-2.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -87.77M -130.76M -124.24M -352.45M 6.12M
Minority interest 0.00M 0.44M -0.24M 0.24M -
Net income -68.62M -108.44M -105.14M -337.26M 10.89M
Selling general administrative 71.10M 77.03M 108.23M 82.44M 30.38M
Selling and marketing expenses 21.14M 20.88M 19.09M 16.65M 3.52M
Gross profit 65.05M 111.17M 165.44M 157.21M 30.16M
Reconciled depreciation 55.93M 57.12M 54.72M 49.32M -
Ebit -31.18M -83.88M -81.22M -322.75M 7.80M
Ebitda 24.75M -26.76M -26.51M -273.42M 15.37M
Depreciation and amortization 55.93M 57.12M 54.72M 49.32M 7.56M
Operating income -30.90M -86.41M -81.46M -27.45M 1.53M
Other operating expenses 543.93M 577.14M 653.88M 575.10M 95.22M
Interest expense 56.59M 46.88M 43.02M 29.70M 1.68M
Tax provision -19.14M -21.88M -19.34M -15.19M -
Net interest income -56.59M -46.88M -43.02M -29.70M -
Income tax expense -19.14M -21.88M -19.34M -15.19M -4.78M
Total revenue 513.02M 490.74M 572.42M 547.66M 89.61M
Total operating expenses 95.95M 197.58M 246.90M 184.66M 35.77M
Cost of revenue 447.97M 379.57M 406.98M 390.44M 59.45M
Total other income expense net -56.87M -44.35M -42.78M -89.00M 0.50M
Net income from continuing ops -68.62M -108.89M -104.90M -337.26M -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 771.11M 781.36M 856.53M 962.90M 321.86M
Intangible assets 240.20M 274.40M 308.43M 345.89M 24.23M
Other current assets 29.67M 46.37M 31.79M 42.95M 21.13M
Total liab 635.09M 610.86M 588.04M 603.13M 216.73M
Total stockholder equity 136.03M 170.50M 269.15M 360.37M 105.13M
Other current liab 64.61M 23.81M 57.87M 103.24M 8.93M
Common stock 8.55M 6.47M 6.41M 6.36M 3.94M
Capital stock 8.55M 6.47M 6.41M 6.36M -
Retained earnings -630.81M -562.16M -453.28M -348.28M -11.02M
Good will 94.29M 94.29M 94.29M 157.82M 51.93M
Cash 21.74M 21.43M 35.49M 18.52M 138.92M
Total current liabilities 556.78M 119.04M 132.19M 164.10M 55.11M
Current deferred revenue 51.51M 41.99M 18.93M 68.64M 26.61M
Net debt 481.89M 423.69M 382.15M 367.98M 35.27M
Short term debt 412.51M 15.31M 18.23M 30.96M 13.39M
Short long term debt 405.12M 3.54M 7.95M 22.98M -
Short long term debt total 503.63M 445.12M 417.64M 386.49M 174.19M
Other stockholder equity 756.06M 724.79M 715.70M 707.79M 112.20M
Total current assets 194.59M 163.41M 213.80M 232.98M 189.02M
Net receivables 97.45M 77.44M 90.42M 100.07M 28.36M
Long term debt - 389.80M 369.80M 330.68M -
Inventory 45.74M 18.17M 56.10M 71.44M 0.60M
Accounts payable 48.53M 33.53M 32.56M 28.70M 6.16M
Accumulated other comprehensive income 2.23M 1.41M 0.33M -5.50M 0.00M
Non currrent assets other 7.32M 5.69M 6.40M 7.52M 0.28M
Non current assets total 576.52M 617.95M 642.73M 729.92M 132.84M
Capital lease obligations 54.16M 52.43M 39.90M 32.84M -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total cashflows from investing activities -12.89M -16.83M -28.75M -333.72M -54.06M
Net borrowings -1.95M 13.55M 17.93M 214.26M -
Total cash from financing activities 23.70M 9.68M 15.87M 203.15M 198.83M
Net income -68.62M -108.89M -104.90M -337.26M 10.89M
Change in cash 0.31M -14.06M 16.51M -137.94M 155.52M
Begin period cash flow 21.43M 35.49M 18.98M 156.92M 1.41M
End period cash flow 21.74M 21.43M 35.49M 18.98M 156.92M
Total cash from operating activities -10.46M -6.80M 27.88M -5.22M 10.75M
Issuance of capital stock 27.52M 0.00M 0.00M 0.00M -
Depreciation 55.93M 57.12M 54.72M 49.32M 6.27M
Other cashflows from investing activities 3.72M 5.48M -2.37M 0.29M 0.00M
Change to inventory -27.59M 38.21M 14.01M -35.20M 0.10M
Change to account receivables -3.83M 14.17M 9.55M -23.84M -11.95M
Other cashflows from financing activities -1.88M -3.87M 0.03M -11.11M -5.98M
Capital expenditures 16.61M 22.31M 27.50M 36.30M 12.47M
Change in working capital -1.14M 52.60M 16.96M -40.28M 9.64M
Stock based compensation 6.03M 6.74M 7.84M 24.20M 1.79M
Other non cash items 18.97M 8.87M 79.08M 316.63M -12.86M
Free cash flow -27.07M -29.11M 0.38M -41.52M -1.73M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TMO
Thermo Fisher Scientific Inc
-17.51
2.54%
671.24 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
-0.25
0.11%
220.36 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd
-
-%
23.77 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd
-0.92
3.87%
22.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Inotiv, Inc.

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana. On June 3, 2026, Inotiv, Inc. along with its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

2701 Kent Avenue, West Lafayette, IN, United States, 47906

765 463 4527

1945

Name Title Year Born
Mr. Robert W. Leasure Jr. President, CEO & Director 1960
Ms. Beth A. Taylor CPA EVP & CFO 1965
Ms. Andrea M. Castetter EVP of General Counsel & Corporate Secretary and Chief Compliance Officer 1978
Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D. Chief Strategy Officer & Director 1966
Dr. Adrian Hardy Ph.D. Chief Commercial Officer 1971
Mr. Brennan Freeman VP of Finance, Principal Accounting Officer & Corporate Controller 1987
Mr. John Gregory Beattie DSA Chief Operating Officer of DSA 1967
Ms. Lizanne Muller Group President of RMS NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…